Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Lexicon Pharmaceuticals Q2 2024 GAAP EPS $(0.17) Beats $(0.19) Estimate, Sales $1.647M Miss $2.831M Estimate

Author: Benzinga Newsdesk | August 01, 2024 04:02pm
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 22.73 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $1.647 million which missed the analyst consensus estimate of $2.831 million by 41.81 percent. This is a 419.56 percent increase over sales of $317.000 thousand the same period last year.

Posted In: LXRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist